EP Vantage 2018 Preview
An uptick in M&A activity and investor cash is expected to
re-invigorate pharma and biotech in 2018
The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines set to hit the market and investor support for the industry remaining strong.
The current business friendly stance at the FDA is unlikely to change next year, while M&A could see an uptick, driven by big pharma and big biotech’s need to re-stock pipelines and US tax reforms.
M&A activity expected to climb after slow 2017 – US tax reform a deciding factor for big deals
Another big year predicted for venture financing as crossover funds return
IPO window expected to remain firmly open
Gilead’s new HIV triplet is the biggest potential new drug launch of 2018, with 2022 sales seen reaching $5bn
Abbvie’s Humira will be biggest selling drug in 2018, with global sales topping $20bn
Merck’s Keytruda will add the most new sales next year, $2.3bn